News

The FDA is requiring additional time to review supplemental data that Baxter provided as part of the ongoing BLA process for HyQvia approval. The PDUFA date has been

TD2 will study the effectiveness of Nuvilex’s pancreatic cancer treatment in relieving the unbearable pain and the accumulation of abdominal fluid known as ‘ascites’. Nuvilex’s pancreatic cancer treatment,

PML is a rare side effect of small molecule and antibody drugs given to patients with autoimmune diseases such as arthritis and multiple sclerosis (MS). It also occurs

ClinPay solution of Clinverse automates sponsor payments to clinical vendors, investigators, and other parties across the entire financial lifecycle of a clinical trial, reducing workload and costs while

DSM Fine Chemicals is a business unit of the newly formed DPx Holding which also owns Patheon Pharma Services and Banner Life Sciences. Relypsa senior vice president of

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound and it functions by binding to the nuclear export protein XPO1 (CRM1), leading to the accumulation

The company said that ABI-009 leverages the same technology of the nab platform that is behind the success of ABRAXANE (paclitaxel protein-bound particles for injectable suspension). Under the

Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for the maintenance treatment of opioid dependence. The drug should be used as part of a comprehensive treatment plan,

Both the firms have not disclosed the details of the agreement, under which AOP Orphan has agreed to specific annual commercial goals for AGGRASTAT. The deal will see